ArticleNeurobiology of aging2016
Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
Article in Neurobiology of aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.Alzheimer's research & therapy · 2018Pooled it
- Recruitment and retention in a preclinical AD trial: comparisons between academic and non-academic sites.Alzheimer's research & therapy · 2025Trial
- Just Semantics? How Diagnostic Criteria Influence Physician-Patient Narratives in Alzheimer's Disease.Neuro-degenerative diseases · 2026Article
- Pathways to participation - a scoping review outlining barriers and enablers to participation in dementia research.The journal of prevention of Alzheimer's disease · 2026Article
- Characterizing the Research Participant Recruitment Funnel for Alzheimer's Secondary Prevention Trials: Results from A National Survey of U.S. Adults.Alzheimer's & dementia. Behavior & socioeconomics of aging · 2025Article
- Understanding participants' attitudes toward research in the CARE registry.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Increasing representation of Asian American, Native Hawaiian, and Pacific Islander communities in aging, dementia, and caregiving research: An update from the CARE registry.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Genetic and biomarker disclosure process in a memory and aging study.Journal of Alzheimer's disease : JAD · 2025Article
- Ethical disclosure of biomarkers for Alzheimer risk in Latin American participants.Frontiers in dementia · 2025Article
- Remote Evaluation of Sleep and Circadian Rhythms in Older Adults With Mild Cognitive Impairment and Dementia: Protocol for a Feasibility and Acceptability Mixed Methods Study.JMIR research protocols · 2024Article
- The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.The journal of prevention of Alzheimer's disease · 2024Article
- Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial.The journal of prevention of Alzheimer's disease · 2024Article
- Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study.Alzheimer's research & therapy · 2023Observational
- Evaluation of the Electronic Clinical Dementia Rating for Dementia Screening.JAMA network open · 2023Observational
- Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Review
- Research Attitude and Interest among Cancer Survivors with or without Cognitive Impairment.Cancers · 2023Article
- US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging.The journal of prevention of Alzheimer's disease · 2023Article
- "I Want to Know Everything ... ": The Return of Research Results and the Importance of Transparency in the Acceptability of Lumbar Punctures for African American Older Adults.Journal of Alzheimer's disease : JAD · 2023Article
- Research attitudes in families of individuals with Down syndrome: importance for clinical trials.Alzheimer's research & therapy · 2022Article
- Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Preclinical Alzheimer's disease (AD) clinical trials may require participants to learn if they meet biomarker enrollment criteria. To examine whether this requirement will impact trial recruitment, we presented 132 older community volunteers who self-reported normal cognition with 1 of 2 hypothetical informed consent forms (ICFs) describing an AD prevention clinical trial. Both ICFs described amyloid Positron Emission Tomography scans. One ICF stated that scan results would not be shared with the participants (blinded enrollment); the other stated that only persons with elevated amyloid would be eligible (transparent enrollment). Participants rated their likelihood of enrollment and completed an interview with a research assistant. We found no difference between the groups in willingness to participate. Study risks and the requirement of a study partner were reported as the most important factors in the decision whether to enroll. The requirement of biomarker disclosure may not slow recruitment to preclinical AD trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.